International trends in clozapine use: a study in 17 countries

Bachmann, C. J., Aagaard, L., Bernardo, M., Brandt, L., Cartabia, M., Clavenna, A., Coma Fusté, A., Furu, K. +26 more·2017·Acta Psychiatrica Scandinavica
DOI 10.1111/acps.12742

Cited by (312)

Items 101–200 of 312

  1. Clozapine in treatment-resistant schizophrenia: Reflections from the Hallmark US clinical trial and beyond
    John Michael Kane, Georgios Schoretsanitis, José M. Rubio, Christoph Ulrich Correll · 2024 · Schizophrenia Research
  2. Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study
    Ebenezer Oloyede, Christian Bachmann, Olubanké Dzahini, Juan Miguel Lopez Alcaraz, Shaurya Dev Singh, Kalliopi Vallianatu, Burkhardt Funk, Eromona Whiskey, David M. Taylor · 2024 · The British Journal of Psychiatry
  3. Early treatment resistance in a Latin-American cohort of patients with schizophrenia
    Cristián Mena, Alfonso González‐Valderrama, Bárbara Iruretagoyena, Juan Pablo Undurraga, Nicolas Andres Crossley · 2018 · Schizophrenia Research
  4. Effect of age on the relative efficacy of clozapine in schizophrenia
    Rowena Jones, James Hunter MacCabe, Malcolm James Price, Xuzhen Liu, Rachel Upthegrove · 2020 · Acta Psychiatrica Scandinavica
  5. Delaying clozapine: how long is too long?
    Tom Varghese M, KS Jyothi, KS Shaji, Lekshmi Rita Venugopal · 2020 · General Psychiatry
  6. Global trends in clozapine utilisation between 2014 and 2024: a longitudinal epidemiological study with data from 75 countries
    Ita Fitzgerald, Sarah O'Dwyer, Ciara Ní Dhubhlaing, Siobhan Gee, Laura Jane Sahm, Amanda Wheeler, Eoin Hurley, Leena Saastamoinen, Anna Waksmundzka-Walczuk, Gráinne Donohue et al. · 2026 · The Lancet Regional Health - Europe
  7. New approaches to antipsychotic medication adherence – safety, tolerability and acceptability
    Sharon Taub, Amir Krivoy, Eromona Whiskey, Sukhwinder Singh Shergill · 2021 · Expert Opinion on Drug Safety
  8. Clozapine-induced Myocarditis: Pathophysiologic Mechanisms and Implications for Therapeutic Approaches
    Simon W. Rabkin, Jacky K. K. Tang · 2022 · Current Molecular Pharmacology
  9. Clinical Outcomes after Clozapine Discontinuation in Patients with Schizophrenia: A Systematic Review
    Gentaro Miura, Kouhei Tanaka, Takashi Kemuriyama, Fuminari Misawa, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuchi · 2022 · Pharmacopsychiatry
  10. Non-prescribing of clozapine for outpatients with schizophrenia in real-world settings: The clinicians’ perspectives
    Michelle Iris Jakobsen, Stephen F. Austin, Ole Jakob Storebø, Jimmi Nielsen, Erik Hertel Simonsen · 2023 · Schizophrenia
  11. When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis
    Mishal Qubad, Gabriele Dupont, Martina Hahn, Simon S. Martin, Valentina O. Püntmann, Eike C. Nagel, Andreas Reif, Robert A. Bittner · 2024 · CNS Drugs
  12. Clozapine Disrupts Endothelial Nitric Oxide Signaling and Antioxidant System for its Cardiovascular Complications
    Gayathri M. Nair, Dona Sheba Skaria, Teenu James, S.K. Kanthlal · 2019 · Drug Research
  13. Cluster Analysis of Clozapine Consumer Perspectives and Comparison to Consumers on Other Antipsychotics
    Sumeet K. Sharma, Sarah L. Kopelovich, A. Umair Janjua, Cristina M. Pritchett, Beth Broussard, Meena Dhir, Joseph G Wilson, David R. Goldsmith, Robert O. Cotes · 2021 · Schizophrenia Bulletin Open
  14. Metabolic predictors for mortality among patients treated with long-term clozapine – A longitudinal study
    Sharon Taub, Moshe Hoshen, Ran D. Balicer, Shiri Kamhi-Nesher, Abraham Weizman, Amir Krivoy · 2020 · European Neuropsychopharmacology
  15. Ethnicity-Based Personalized Clozapine Titration Strategies for Prevention of Clozapine-Induced Inflammation: Recommendations Based on Evidence from the Japanese Population
    Yuki Kikuchi, Bunichiro Onodera, Hiroshi Komatsu, Hiroaki Tomita · 2025 · CNS Drugs
  16. Prescribing clozapine to 10% of patients with schizophrenia may save 320,000 lives and cost 2400 deaths from agranulocytosis
    José de León · 2025 · European Neuropsychopharmacology
  17. Antipsychotic prescribing practices for outpatients with schizophrenia and reasons for non-clozapine treatment - Data from a Danish quality assessment audit
    Michelle Iris Jakobsen, Julie Perrine Schaug, Jimmi Nielsen, Erik Hertel Simonsen · 2023 · Nordic Journal of Psychiatry
  18. A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study
    Tomihisa Niitsu, Tatsuki Hata, Masahiko Nishimoto, Yutaka Hosoda, Atsushi Kimura, Yasunori Oda, Masatoshi Suzuki, Naoko Takase, Ryota Seki, Kiyoshi Fujita et al. · 2020 · Asian Journal of Psychiatry
  19. Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues
    Jonathan G. Leung, Megan J. Ehret, Raymond C. Love, Robert O. Cotes · 2023 · Expert Review of Clinical Pharmacology
  20. The pharmacological treatment of schizophrenia: how far have we come?
    Rubio, Jose M., Kane, John M. · 2022 · Psychiatry and Clinical Neurosciences Reports
  21. Clozapine Is Better Tolerated in Younger Patients: Risk Factors for Discontinuation from a Nationwide Database in Japan
    Katsunori Toyoda, Takeo Hata, Shigeru Yamauchi, Shinya Kinoshita, Masami Nishihara, Kazuhisa Uchiyama, Ken Inada, Tetsufumi Kanazawa · 2021 · Psychiatry Investigation
  22. Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis
    Lik Hang N. Lee, Ric M. Procyshyn, Randall F. White, Todd Stephen Woodward, William G. Honer, Alasdair M. Barr · 2018 · PLoS ONE
  23. Environmentally relevant concentrations of clozapine induced lipotoxicity and gut microbiota dysbiosis in Chinese rare minnow (Gobiocypris rarus)
    Jiajing Xin, Saihong Yan, Xiangsheng Hong, Huan Zhang, Jinmiao Zha · 2021 · Environmental Pollution
  24. Antipsychotic utilisation and persistence in Australia: A nationwide 5-year study
    M. Taylor, D. Dangelo-Kemp, Dennis Liu, S. Kisely, Simon Graham, J. Hartmann, S. Colman · 2021 · Australian and New Zealand journal of psychiatry (Print)
  25. Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options
    José M. Rubio, Daniel Guinart, John Michael Kane, Christoph Ulrich Correll · 2023 · CNS Drugs
  26. Temporal trends in clozapine use at time of discharge among people with schizophrenia at two public psychiatric hospitals in Taiwan, 2006–2017
    Ching‐Hua Lin, Hung‐Yu Chan, Chun‐Chi Hsu, Feng-Chua Chen · 2020 · Scientific Reports
  27. Worldwide antipsychotic drug search intensities: pharmacoepidemological estimations based on Google Trends data
    Richard Ågren · 2021 · Scientific Reports
  28. Antipsychotic-Related Fatal Poisoning, England and Wales, 1993–2019
    Simon Alfred Handley, Susanna Every‐Palmer, Robert James Flanagan · 2021 · Journal of Clinical Psychopharmacology
  29. Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review
    Olivier Corbeil, Laurent Béchard, Émilien Fournier, Maude Plante, Marc-André Thivierge, Charles-Émile Lafrenière, Maxime Huot‐Lavoie, Sébastien Brodeur, Anne‐Marie Essiambre, Marc‐André Roy et al. · 2023 · Journal of Psychopharmacology
  30. Clozapine: past, present and future
    Christoph U. Correll · 2025 · World Psychiatry
  31. Family psychoeducation in schizophrenia and schizophrenia related disorder, treatment compliance, and suicidal risk reduction: questions about their relationship from a naturalistic observation
    Yann Hodé, Romain Padovani, Wydad Hikmat, Nathalie Guillard-Bouhet, Jérôme Attal, Marie‐Cécile Bralet, Mélanie Biotteau, Isabelle Chéreau, Olivier Canceil, Aurélie Montagne Larmurier et al. · 2024 · Frontiers in Psychiatry
  32. A mixed methods analysis of clozapine errors reported to the National Reporting and Learning System
    Keval Dabba, Matthew Elswood, Ahmed Ameer, David Gerrett, Ian D. Maidment · 2019 · Pharmacoepidemiology and Drug Safety
  33. Delegating Clozapine Monitoring to Advanced Nurse Practitioners: An Exploratory, Randomized Study to Assess the Effect on Prescription and Its Safety
    CLOZ-NP Study Group, Yvonne C. van der Zalm, Peter F.J. Schulte, Jan P.A.M. Bogers, Fabian Termorshuizen, Machteld C. Marcelis, M. A. G. B. van Piere, Iris E. Sommer, Jean‐Paul Selten · 2020 · Administration and Policy in Mental Health and Mental Health Services Research
  34. Clozapine prescription rates in Southeast Europe: A cross-sectional study
    Manuela Russo, Dragana Ignjatović Ristić, Dan Cohen, Aliriza Arënliu, Stojan Bajraktarov, Alma Džubur Kulenović, Lidija Injac Stevović, Nadja P. Marić, Antoni Novotni, Nikolina Jovanović · 2023 · Frontiers in Psychiatry
  35. Which components of specialized early intervention for psychosis do senior providers see as most important?
    Mark Savill, Angela Sardo, Pooja Patel, Rachel L. Loewy, Joy A. Melnikow, Tara A. Niendam · 2018 · Early Intervention in Psychiatry
  36. No adverse events were observed in clozapine‐treated patients on extended hematologic monitoring intervals during the coronavirus pandemic in four psychiatric centers in Japan
    Masahiro Hata, Michiko Fujimoto, Koji Kanai, Kenji Yoshiyama, Yoshitaka Nakatani, Daiji Nakabayashi, Saki Maemura, Shinya Kawata, Takaaki Hakozaki, Shuya Nishikura et al. · 2021 · Neuropsychopharmacology Reports
  37. A scoping review of literature on clozapine from former USSR states published in Russian language
    Oleg O. Kirilochev, Egor M. Chumakov, Nazar Kuzo, Georgios Schoretsanitis · 2023 · Schizophrenia Research
  38. Duration of prior psychotic illness and clozapine response: a retrospective observational study using electronic health records
    Rowena Jones, Rachel Upthegrove, Malcolm James Price, Megan Pritchard, Joht Singh Chandan, Sophie E. Legge, James Hunter MacCabe · 2022 · Therapeutic Advances in Psychopharmacology
  39. Genetic contribution to disease-course severity and progression in the SUPER-Finland study, a cohort of 10,403 individuals with psychotic disorders
    Anders J. Kämpe, Jaana Suvisaari, Markku Lähteenvuo, Tarjinder Singh, Ari Ahola‐Olli, Lea Urpa, Willehard Haaki, Jarmo A. Hietala, Erkki Tapio Isometsä, Tuomas Jukuri et al. · 2024 · Molecular Psychiatry
  40. What is the current scope of research assessing patients’ and clinicians’ perspectives on clozapine treatment? A comprehensive scoping review
    Michelle Iris Jakobsen, Julie Perrine Schaug, Ole Jakob Storebø, Stephen F. Austin, Jimmi Nielsen, Erik Hertel Simonsen · 2025 · BMJ Open
  41. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature
    Carlos De las Cuevas, Emílio J. Sanz, José de León · 2025 · Expert Opinion on Drug Safety
  42. Hematological and Other Cancers in People Using Clozapine
    Jessica L. Dawson, Janet Kathleen Sluggett, Nicholas Gerard Procter, Nicholas Myles, J. Simon Bell · 2023 · Journal of Clinical Psychopharmacology
  43. Infections associated with clozapine: a pharmacovigilance study using VigiBase®
    Basile Chrétien, Perrine Brazo, Angélique Da Silva, Marion Sassier, Charles Dolladille, Véronique Lelong‐Boulouard, Joachim Alexandre, Sophie Fédrizzi · 2023 · Frontiers in Pharmacology
  44. A brief history and challenges of clozapine utilization in the Arab world
    Monica Zolezzi, Yassin Hassan Eltorki · 2023 · Schizophrenia Research
  45. Mandatory certification for clozapine prescribing
    Dan Cohen, Saeed Farooq · 2020 · European Psychiatry
  46. Predictors of clozapine discontinuation at 2 years in treatment-resistant schizophrenia
    Bárbara Iruretagoyena, Carmen Paz Castañeda, Cristián Mena, Camila Díaz, Rubén Nachar, Juan Pablo Ramírez-Mahaluf, Alfonso González‐Valderrama, Juan Pablo Undurraga, James Hunter MacCabe, Nicolas Andres Crossley · 2021 · Schizophrenia Research
  47. Prescription and Underprescription of Clozapine in Dutch Ambulatory Care
    Yvonne C. van der Zalm, Fabian Termorshuizen, Peter F.J. Schulte, Jan P.A.M. Bogers, Machteld C. Marcelis, Iris E. Sommer, Jean‐Paul Selten · 2018 · Frontiers in Psychiatry
  48. Response to clozapine and its predictors in treatment-resistant schizophrenia spectrum disorders: A retrospective chart review
    Rajkumar Sanahan, Vanteemar Sathyanarayana Sreeraj, Satish Suhas, Vijay Kumar, Jagadisha Thirthalli, Ganesan Venkatasubramanian · 2024 · Schizophrenia Research
  49. Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment
    Marina Garriga, Andrea Mallorquí, Sonia Bernad, Victoria Ruiz-Cortes, Cristina Oliveira, Sílvia Amoretti, Gisela Mezquida, Miquel Bioque, Oriol Molina, Marta Gómez-Ramiro et al. · 2021 · Journal of Clinical Psychopharmacology
  50. Functioning and cognitive characteristics of clozapine users referred to psychosocial rehabilitation centers: A REHABase cohort study.
    H. Verdoux, C. Quiles, S. Cervello, J. Dubreucq, Laura Bon, C. Massoubre, R. Pommier, E. Legros-Lafarge, N. Jaafari, N. Guillard-Bouhet et al. · 2019 · Psychiatry Research
  51. Fatal poisonings involving clozapine: A 16-year review of Australian coronial investigations
    Jessica L. Dawson, Janet Kathleen Sluggett, Jennifer Schumann, Nicholas Gerard Procter, J. Simon Bell · 2021 · Australian & New Zealand Journal of Psychiatry
  52. Neutrophil Myeloperoxidase-Mediated N-Demethylation of Quetiapine Leads to N-Desalkylquetiapine, a Pharmacologically Active Cytochrome P450 Metabolite
    Md. Harunur Rashid, Dinesh Babu, Newton H. Tran, Béla Reiz, Arno G. Siraki · 2022 · Chemical Research in Toxicology
  53. Clozapine prescribing practice and trends in Qatar: First national observational study
    Ovais Wadoo, Javed Latoo, Majid Alabdulla, Yassin Hassan Eltorki, Sadaf Riaz, Mustafa Abdul Karim, Mohammed Abu-Hafizah, Shuja Mohd Reagu · 2022 · Brain and Behavior
  54. Clozapine use – has practice changed?
    Roberta Rowntree, Séan Murray, Felicity Fanning, Dolores Keating, Atilla Szigeti, Roisin Doyle, Stephen McWilliams, Mary Clarke · 2020 · Journal of Psychopharmacology
  55. Real-world effectiveness of antipsychotic treatments in 1011 acutely hospitalized patients with schizophrenia: A one-year follow-up study
    Kotaro Hatta, Shigemasa Katayama, Takuya Ishizuka, Yasuhiko Sudo, Mitsuru Nakamura, Hana Hasegawa, Atsushi Imai, Fumiyoshi Morikawa, Tatsuhiro Shimada, Fuminari Misawa et al. · 2021 · Asian Journal of Psychiatry
  56. Determinants of patient satisfaction in clozapine users: results from the Clozapine International Consortium (CLOZIN)
    Marte Z. van der Horst, Nini de Boer, CLOZIN collaborators, Ahmet Müderrisoğlu, Alba Toll, Alde Bouhuis, Alkomiet Hasan, Amy Jongkind, Ana María González-Pinto, Anna Mané et al. · 2025 · Schizophrenia
  57. Fatal Abdominal Compartment Syndrome Due to Constipation: A Case Report
    Matthew Kongkatong, Malav Patel, Christopher D. Thom, James H. Moak · 2022 · Clinical Practice and Cases in Emergency Medicine
  58. Schizophrenia and Related Psychoses
    2021 · Wiley eBooks
  59. Psychiatrists’ views on clozapine prescribing in Ireland
    A. Grant, Ross McManus, Hiberet Tessema Belay, M. Mahon, F. Murad, Brian N. O'Donoghue, John Lally · 2024 · Irish Journal of Psychological Medicine
  60. Neurodevelopmental predictors of treatment response in schizophrenia and bipolar disorder
    Anton Iftimovici, Emma Krebs, William Dalfin, Adrien Legrand, Linda Scoriels, Gilles Martínez, Narjès Bendjemaa, Édouard Duchesnay, Boris Chaumette, Marie‐Odile Krebs · 2024 · Psychological Medicine
  61. Perspectives of clozapine-naïve outpatients with treatment-resistant schizophrenia on clozapine commencement: a mixed-methods convergent study
    Michelle Iris Jakobsen, Stephen F. Austin, Ole Jakob Storebø, Erik Hertel Simonsen, Jimmi Nielsen · 2025 · BMJ Open
  62. Lower sertraline plasma concentration in patients co‐medicated with clozapine—Implications for pharmacological augmentation strategies in schizophrenia
    Arnim Johannes Gaebler, Ekkehard Haen, Nagia Ben Omar, Katharina Endres, Christoph Hiemke, Georgios Schoretsanitis, Michael Paulzen · 2023 · Pharmacology Research & Perspectives
  63. Hepatotoxicity of antipsychotics: an exploratory pharmacoepidemiologic and pharmacodynamic study integrating FAERS data and in vitro receptor-binding affinities
    René Zeiss, Carlos Schönfeldt‐Lecuona, Bernhard J. Connemann, Susanne Häfner, Maximilian Gahr · 2024 · Frontiers in Psychiatry
  64. A Pharmacovigilance Study on Clozapine in the Food and Drug Administration Adverse Event Reporting System: A Regional Comparative Analysis
    Masakazu Hatano, Haruna Araki, Takeo Saito, Shigeki Yamada · 2024 · Clinical Psychopharmacology and Neuroscience
  65. Community pharmacists’ attitudes and opinions towards supplying clozapine
    Yuh-Lin Gan, Claire Louise O’Reilly · 2018 · International Journal of Clinical Pharmacy
  66. Mentally disordered offenders discharged from designated hospital facilities under the medical treatment and supervision act in Japan: Reoffending and readmission
    Takako Nagata, Hisateru Tachimori, Hirofumi Nishinaka, Koji Takeda, Taro Matsuda, Naotsugu Hirabayashi · 2019 · Criminal Behaviour and Mental Health
  67. Clozapine Use in Patients with Early-Stage Schizophrenia in a Chinese Psychiatric Hospital
    Wenying Yi, Shenglin She, Jie Zhang, Haibo Wu, Yingjun Zheng, Yuping Ning · 2020 · Neuropsychiatric Disease and Treatment
  68. Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives
    Alexis Revet, Guillaume Moulis, Jean‐Philippe Raynaud, Éric Bui, Maryse Lapeyre‐Mestre · 2021 · Fundamental and Clinical Pharmacology
  69. Clozapine and Regulatory Inertia: Revisiting Evidence, Risks, and Reform
    Carlos De las Cuevas · 2025 · Healthcare
  70. Trajectories of Clozapine Concentrations in Women Across Menopausal Age
    Franciska de Beer, Iris M. H. Hamers, Michalina Prycka, Georgios Schoretsanitis, Shiral S. Gangadin, Daan Johannes Touw, Iris E. Sommer · 2025 · Schizophrenia Bulletin
  71. Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine
    Kohei Kitagawa, Shusuke Uekusa, Yuki Hanai, Itsuki Kimura, Masaru Tsukahara, Azusa Kagawa, Kenji Sasaoka, Yui Sakishiro, Ayaka Miyake, Yūki Watanabe et al. · 2024 · Asian Journal of Psychiatry
  72. Clozapine as a mood stabiliser for schizoaffective disorder: Effectiveness during a three-month follow-up
    Marc Peraire, Francisco Arnau, Ana Benito, Alejandro Fuertes-Sáiz, Isabel Almodóvar-Fernández, Gonzalo Haro · 2024 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  73. Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates
    Mirza Detanac, Chelsey Williams, Milan Dragović, Gordon Shymko, Alexander Panickacheril John · 2024 · Australian & New Zealand Journal of Psychiatry
  74. Molecular Underpinning of Treatment-Resistant Schizophrenia: A Putative Different Neurobiology from Treatment-Responsive Schizophrenia
    Annarita Barone, Licia Vellucci, Mariateresa Ciccarelli, Marta Matrone, Giuseppe De Simone, Federica Iannotta, Felice Iasevoli, Andrea de Bartolomeis · 2025 · International Journal of Molecular Sciences
  75. Differences between counties in the prescribing of clozapine
    Morten Brix Schou, Ole Kristian Drange, Sverre Georg Sæther · 2019 · Tidsskrift for Den norske legeforening
  76. Rates and Reasons for Clozapine Treatment Interruptions
    Alexander Panickacheril John, Susanne H. Stanley, Darren Haywood · 2023 · Journal of Clinical Psychopharmacology
  77. Reliability of the Glasgow Antipsychotic Side-effects Scale for Clozapine Japanese version (GASS-C-J)
    Kohei Kitagawa, Ryuhei So, Nobuyuki Nomura, Yuya Mizuno, Fuminari Misawa, Masafumi Kodama, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuchi · 2020 · PLoS ONE
  78. Risk of neutropenia among clozapine users and non-users: results from 5,847 patients
    André Akira Sueno Goldani, Francisco Diego Rabelo‐da‐Ponte, Jacson Gabriel Feiten, Maria Inês Rodrigues Lobato, Paulo Silva Belmonte-de-Abreu, Clarissa Severino Gama · 2021 · Brazilian Journal of Psychiatry
  79. Myocarditis During Treatment With Clozapine in 2 Adolescent Cases
    Susanne Mudra, Daniel Luedecke, Maria Grafmann, Michael Schulte‐Markwort · 2018 · Journal of Clinical Psychopharmacology
  80. Benzodiazepines and clozapine co-prescription in clinical practice: a systematic review and expert recommendations
    Clélia Quilès, José de León, Hélène Verdoux · 2025 · Expert Opinion on Drug Metabolism & Toxicology
  81. Evaluation of 96 cases of apparent clozapine-induced severe neutropenia
    Phoebe Wallman, Risha Govind, Cecilia Casetta, Eromona Whiskey, Shreyans Gandhi, Amelia Jewell, James Hunter MacCabe, David M. Taylor · 2025 · The British Journal of Psychiatry
  82. A Randomized Controlled Trial of an Extension for Community Healthcare Outcomes (ECHO) Tele-mentoring Program to Increase Clozapine Utilization
    Deanna L. Kelly, Jared Hunt, Gopal R. Vyas, Matthew Glassman, Clayton H Brown, Fang Li, Heidi J. Wehring, Raymond C. Love, Elaine Weiner, Gloria M. Reeves et al. · 2025 · Schizophrenia Bulletin
  83. Evaluation of the toxicity of clozapine on the freshwater diatom Navicula sp. using the FTIR spectroscopy
    Haojun Lei, Xin-Rong Wei, Li-Xia Li, Wei-Jun Sun, Hongxing Chen, Dan Li, Lingtian Xie · 2023 · Chemosphere
  84. Clozapine treatment of a Japanese patient during pregnancy: Effect on fetal heart rate
    Shunya Aoki, Katsutoshi Takada, Tatsuru Sugama, Mitsugi Kimiwada, Tatsuya Hoshino, Takaoki Kaneko, Shintaro Obata, Yasuhiro Ota, Satoshi Toishi, Kaori Koike et al. · 2024 · Neuropsychopharmacology Reports
  85. Patients’ and psychiatrists’ perspectives on clozapine treatment—a scoping review protocol
    Michelle Iris Jakobsen, Ole Jakob Storebø, Stephen F. Austin, Jimmi Nielsen, Erik Hertel Simonsen · 2021 · BMJ Open
  86. Trends in mortality in schizophrenia and their implications
    Ellis Chika Onwordi, Oliver David Howes · 2018 · Acta Psychiatrica Scandinavica
  87. Clozapine for older adults with severe mental illness: a systematic review and expert recommendations for clinical practice
    Hélène Verdoux, Alexis Lepetit, José de León · 2025 · Expert Review of Clinical Pharmacology
  88. Physical health examination in outpatients with schizophrenia: the cost effectiveness of laboratory screening tests
    Saana Eskelinen, Janne V. J. Suvisaari, Jaana Suvisaari · 2020 · Annals of General Psychiatry
  89. Demographic and clinical characteristics of patients who recommence clozapine following therapy interruptions
    Alexander Panickacheril John, Sally Burrows, Susanne H. Stanley, Cherry Acabo, Gordon Shymko, Aleksandra Jaworska, Ajay Velayudhan · 2021 · Acta Psychiatrica Scandinavica
  90. Clozapine use at a specialised psychiatric hospital in Johannesburg
    Katherine L. Ord, Belinda Marais · 2023 · South African Journal of Psychiatry
  91. Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide study
    Shinichiro Ochi, Fumitoshi Kodaka, Naomi Hasegawa, Takashi Tsuboi, Kazutaka Ohi, Shun Igarashi, Kentaro Fukumoto, Jun‐ichi Iga, Hiroyuki Muraoka, Hitoshi Iida et al. · 2025 · The International Journal of Neuropsychopharmacology
  92. Current perspectives on the recognition and management of treatment-resistant schizophrenia: challenges and opportunities
    Myrto T. Samara, Georgios A. Alevizopoulos, Vasilis P. Bozikas, Ioannis Chatzimanolis, Dimitris G. Dikeos, Theodoros Mougiakos, Anastasia Nikolaou, Dimitrios Sakellariou, Charalampos Touloumis, Christos Tsopelas et al. · 2025 · Expert Review of Neurotherapeutics
  93. Prescribing trends in treatment-resistant schizophrenia
    Aynur Görmez, Ayşe Kurtulmuş, Can Tuncer, Serhat Çıtak · 2017 · Psychiatry and Clinical Psychopharmacology
  94. A COMMENTARY ON IMPROVING CLOZAPINE ACCESSIBILITY AND REDUCING TREATMENT COST
    Ronald J. Gurrera · 2020 · Psychiatry Research
  95. ‘Opening doors’ for long‐term institutionalised patients with schizophrenia in Japan
    Tomoyasu Wakuda, Nori Takei · 2020 · Acta Psychiatrica Scandinavica
  96. Clozapine use and prevalence in Australia 2016–2020
    Samantha Hollingworth, Adrian Oliver, Karl Winckel, Dan J. Siskind · 2021 · Australian & New Zealand Journal of Psychiatry
  97. Effectiveness of Clozapine Compared to Nonclozapine Antipsychotics in Older Adults With Schizophrenia in Brazil in a 16-Year Follow-Up
    Júlio César Menezes Vieira, Edna Afonso Reis, Wallace Mateus Prata, Helian Nunes de Oliveira, Cristina Mariano Ruas, Augusto Afonso Guerra · 2025 · American Journal of Geriatric Psychiatry
  98. Metabolic Problems Among People With Treatment-Resistant Schizophrenia are Not Unique to Clozapine
    Alexander Panickacheril John, Hitesh Prajapati, Milan Dragović · 2025 · Journal of Clinical Psychopharmacology
  99. Declines and pronounced state-level variation in clozapine use among Medicare patients
    Luke R. Cavanah, Maria Y. Tian, Jessica L. Goldhirsh, Leighton Y. Huey, Brian J. Piper · 2025 · PLoS ONE
  100. Clozapine prescribing in treatment-resistant schizophrenia – an updated systematic literature review of barriers and facilitators among clinicians
    Siobhán Nolan, Laura Jane Sahm, Ita Fitzgerald · 2026 · European Journal of Clinical Pharmacology